INT36960

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1987
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 33
Total Number 34
Disease Relevance 20.77
Pain Relevance 6.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
lymph node 3
posterior 2
body 2
embryo 1
CAR 1
vs (Mus musculus)
Pain Link Frequency Relevance Heat
medulla 10 100.00 Very High Very High Very High
analgesia 18 99.98 Very High Very High Very High
cINOD 66 99.96 Very High Very High Very High
tramadol 163 99.68 Very High Very High Very High
Central grey 231 99.10 Very High Very High Very High
adenocard 63 97.84 Very High Very High Very High
Bioavailability 7 97.84 Very High Very High Very High
Arthritis 51 95.84 Very High Very High Very High
Inflammation 168 95.64 Very High Very High Very High
imagery 26 93.12 High High
Disease Link Frequency Relevance Heat
Melanoma 303 100.00 Very High Very High Very High
Lymphedema 90 100.00 Very High Very High Very High
Pressure And Volume Under Development 53 99.98 Very High Very High Very High
Obesity 34 99.96 Very High Very High Very High
Urological Neuroanatomy 231 99.10 Very High Very High Very High
Death 48 98.76 Very High Very High Very High
Stroke 181 98.26 Very High Very High Very High
Cancer 194 97.92 Very High Very High Very High
Hypoxia 195 97.64 Very High Very High Very High
Disease 153 97.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
7 vs sham surgery controls), 139.8±8.5% in NSAID-treated mice (P<0.05 vs lymphedema), and 183.7±26.8% in sTNF-R1-treated mice (P<0.005 vs lymphedema).
Gene_expression (lymphedema) of vs associated with cinod and lymphedema
1) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2791214 Disease Relevance 0.92 Pain Relevance 0.37
expression to control levels (P<0.05 vs NSAID).
Gene_expression (expression) of vs associated with cinod
2) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2791214 Disease Relevance 0.47 Pain Relevance 0.57
The analgesia produced by VS is independent of the elevation in BP produced by VS.
Gene_expression (produced) of VS associated with pressure and volume under development and analgesia
3) Confidence 0.38 Published 1987 Journal Physiol. Behav. Section Abstract Doc Link 3441531 Disease Relevance 0.89 Pain Relevance 0.45
The analgesia produced by VS is independent of the elevation in BP produced by VS.
Gene_expression (produced) of VS associated with pressure and volume under development and analgesia
4) Confidence 0.38 Published 1987 Journal Physiol. Behav. Section Abstract Doc Link 3441531 Disease Relevance 0.87 Pain Relevance 0.44
Clinical parameters predicting poor survival outcome that were included in the multivariate analysis were as follows: age (> 50 years vs = 50 years), gender (female vs male), primary site (oral and genitoruinary vs the other mucosal melanomas), lymph node status (N0-1 vs N2-3), complete resectability (R0 vs R1 resection).
Gene_expression (resection) of vs in lymph node associated with melanoma
5) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2880296 Disease Relevance 0.33 Pain Relevance 0
Clinical parameters predicting poor survival outcome that were included in the multivariate analysis were as follows: age (> 50 years vs = 50 years), gender (female vs male), primary site (oral and genitoruinary vs the other mucosal melanomas), lymph node status (N0-1 vs N2-3), complete resectability (R0 vs R1 resection).
Gene_expression (resection) of vs in lymph node associated with melanoma
6) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2880296 Disease Relevance 0.32 Pain Relevance 0
Clinical parameters predicting poor survival outcome that were included in the multivariate analysis were as follows: age (> 50 years vs = 50 years), gender (female vs male), primary site (oral and genitoruinary vs the other mucosal melanomas), lymph node status (N0-1 vs N2-3), complete resectability (R0 vs R1 resection).
Gene_expression (resection) of vs in lymph node associated with melanoma
7) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2880296 Disease Relevance 0.33 Pain Relevance 0
Preliminary experiments were performed comparing diet-induced obese (DIO) vs lean mice prior to conducting experiments on HFD-fed GhrR KO vs WT mice (Figure 1).


Gene_expression (lean) of vs associated with obesity
8) Confidence 0.30 Published 2011 Journal BMC Physiol Section Body Doc Link PMC3024223 Disease Relevance 0.43 Pain Relevance 0
Preliminary experiments were performed comparing diet-induced obese (DIO) vs lean mice prior to conducting experiments on HFD-fed GhrR KO vs WT mice (Figure 1).


Gene_expression (lean) of vs associated with obesity
9) Confidence 0.30 Published 2011 Journal BMC Physiol Section Body Doc Link PMC3024223 Disease Relevance 0.43 Pain Relevance 0.05
More importantly, the survival rate was significantly increased only by the D6 treatment (Figure 6, panel D: D6 vs control, P = 0.0007; D6 vs D1, P = 0.0169).
Gene_expression (control) of vs
10) Confidence 0.29 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2898702 Disease Relevance 0.90 Pain Relevance 0.05
The pronounced delay in tumor growth, especially by D6, was translated into tumor weight values, which have been obtained at the end of the treatment (Figure 6, panel B: both D1 and D6 vs control, ***, P < 0.001; D6 vs D1, *, P < 0.05).
Gene_expression (control) of vs associated with cancer
11) Confidence 0.29 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2898702 Disease Relevance 0.95 Pain Relevance 0.04
We focus on a set of criteria for approach (2) that produce about the same ratio of “true” genes to total genes (“true”+“chance”) (0.43 vs 0.47) as those likely to be observed using the criteria on which we focused in approach (1).
Gene_expression (produce) of vs
12) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2809089 Disease Relevance 0 Pain Relevance 0
7), 0.54 for iso1 vs ctr (p?
Gene_expression (0.54) of vs
13) Confidence 0.23 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2722085 Disease Relevance 0.53 Pain Relevance 0
They found that the factors that did not affect delay included subtype of inflammatory arthritis, the discipline of referring practitioner, age at disease onset, presence of ANA, HLA-B27, RF, visible swelling of joints, involvement of any particular joint, number of joints and place of residence (rural vs urban).
Gene_expression (urban) of vs in joints associated with pressure and volume under development, inflammation, disease and arthritis
14) Confidence 0.18 Published 2008 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2430218 Disease Relevance 0.74 Pain Relevance 0.36
production up to 497±24 pg/ml vs. 40±10 (## P<0.05) in the control.
Gene_expression (production) of vs
15) Confidence 0.18 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2634966 Disease Relevance 0.38 Pain Relevance 0.27
l) into the PAG induced a significant increase in PWL in CFA injected rats (ipsilateral: 11.8 ± 1.2 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5B; contralateral: 12.1 ± 1.4 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5C).
Gene_expression (microinjection) of vs associated with central grey
16) Confidence 0.17 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.93 Pain Relevance 0.56
l) into the PAG (ipsilateral: 11.2 ± 1.1 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5B; contralateral: 11.5 ± 1.6 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5C).


Gene_expression (microinjection) of vs associated with central grey
17) Confidence 0.17 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.80 Pain Relevance 0.53
The amplitude, not the frequency of NMDAR-mediated mEPSCs was significantly increased at LPAG synapses of CFA-injected mice compared with saline controls (Frequency: saline, 0.38 ± 0.07 Hz, CFA, 0.45 ± 0.07 Hz, n = 8; amplitude: saline, 9.4 ± 1.0 pA, CFA, 13.8 ± 1.4 pA, n = 8, p < 0.05 vs saline; Fig. 3).
Gene_expression (saline) of vs in synapses associated with central grey
18) Confidence 0.17 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.75 Pain Relevance 0.40
0.5 pA, vs bicu + ET: 12.1+/?
Gene_expression (bicu) of vs
19) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948003 Disease Relevance 0 Pain Relevance 0.17
Syn3 acts as a transfer enhancer that circumvents the need for CAR binding (119).A comparison of intravesical instillation (single administration) of viral IFN gene therapy (Ad-IFN/Syn3, recombinant replication-deficient adenovirus containing human IFN alpha-2b gene and Syn3) to intravesical IFN showed that IFN gene therapy resulted in much higher IFN concentrations (1000-times higher peak level) that were sustained for a much longer duration (96 hr or longer vs undetectable at 24 hr) in urothelial tissues (121).
Gene_expression (undetectable) of vs in CAR
20) Confidence 0.13 Published 2008 Journal Pharm Res Section Body Doc Link PMC2440939 Disease Relevance 0.13 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox